187 related articles for article (PubMed ID: 29654623)
1. An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.
Josephs DH; Nakamura M; Bax HJ; Dodev TS; Muirhead G; Saul L; Karagiannis P; Ilieva KM; Crescioli S; Gazinska P; Woodman N; Lombardelli C; Kareemaghay S; Selkirk C; Lentfer H; Barton C; Canevari S; Figini M; Downes N; Dombrowicz D; Corrigan CJ; Nestle FO; Jones PS; Gould HJ; Blower PJ; Tsoka S; Spicer JF; Karagiannis SN
Allergy; 2018 Dec; 73(12):2328-2341. PubMed ID: 29654623
[TBL] [Abstract][Full Text] [Related]
2. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
[TBL] [Abstract][Full Text] [Related]
3.
Williams IP; Crescioli S; Sow HS; Bax HJ; Hobbs C; Ilieva KM; French E; Pellizzari G; Cox V; Josephs DH; Spicer JF; Karagiannis SN; Mele S
MAbs; 2020; 12(1):1685349. PubMed ID: 31769737
[TBL] [Abstract][Full Text] [Related]
4. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.
Karagiannis SN; Bracher MG; Hunt J; McCloskey N; Beavil RL; Beavil AJ; Fear DJ; Thompson RG; East N; Burke F; Moore RJ; Dombrowicz DD; Balkwill FR; Gould HJ
J Immunol; 2007 Sep; 179(5):2832-43. PubMed ID: 17709497
[TBL] [Abstract][Full Text] [Related]
5. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states.
Pellizzari G; Hoskin C; Crescioli S; Mele S; Gotovina J; Chiaruttini G; Bianchini R; Ilieva K; Bax HJ; Papa S; Lacy KE; Jensen-Jarolim E; Tsoka S; Josephs DH; Spicer JF; Karagiannis SN
EBioMedicine; 2019 May; 43():67-81. PubMed ID: 30956175
[TBL] [Abstract][Full Text] [Related]
6. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.
Karagiannis SN; Josephs DH; Karagiannis P; Gilbert AE; Saul L; Rudman SM; Dodev T; Koers A; Blower PJ; Corrigan C; Beavil AJ; Spicer JF; Nestle FO; Gould HJ
Cancer Immunol Immunother; 2012 Sep; 61(9):1547-64. PubMed ID: 22139135
[TBL] [Abstract][Full Text] [Related]
7. Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.
Josephs DH; Bax HJ; Lentfer H; Selkirk C; Spicer JF; Karagiannis SN
Lancet; 2015 Feb; 385 Suppl 1():S53. PubMed ID: 26312875
[TBL] [Abstract][Full Text] [Related]
8. Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.
Josephs DH; Bax HJ; Dodev T; Georgouli M; Nakamura M; Pellizzari G; Saul L; Karagiannis P; Cheung A; Herraiz C; Ilieva KM; Correa I; Fittall M; Crescioli S; Gazinska P; Woodman N; Mele S; Chiaruttini G; Gilbert AE; Koers A; Bracher M; Selkirk C; Lentfer H; Barton C; Lever E; Muirhead G; Tsoka S; Canevari S; Figini M; Montes A; Downes N; Dombrowicz D; Corrigan CJ; Beavil AJ; Nestle FO; Jones PS; Gould HJ; Sanz-Moreno V; Blower PJ; Spicer JF; Karagiannis SN
Cancer Res; 2017 Mar; 77(5):1127-1141. PubMed ID: 28096174
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2.
Pellizzari G; Martinez O; Crescioli S; Page R; Di Meo A; Mele S; Chiaruttini G; Hoinka J; Batruch I; Prassas I; Grandits M; López-Abente J; Bugallo-Blanco E; Ward M; Bax HJ; French E; Cheung A; Lombardi S; Figini M; Lacy KE; Diamandis EP; Josephs DH; Spicer J; Papa S; Karagiannis SN
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34112739
[TBL] [Abstract][Full Text] [Related]
10. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
[TBL] [Abstract][Full Text] [Related]
11. Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactions.
Belostotsky R; Lorberboum-Galski H
Clin Immunol; 2004 Jan; 110(1):89-99. PubMed ID: 14962800
[TBL] [Abstract][Full Text] [Related]
12. Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.
Saul L; Josephs DH; Cutler K; Bradwell A; Karagiannis P; Selkirk C; Gould HJ; Jones P; Spicer JF; Karagiannis SN
MAbs; 2014; 6(2):509-22. PubMed ID: 24492303
[TBL] [Abstract][Full Text] [Related]
13. IgE-based immunotherapy of cancer: challenges and chances.
Singer J; Jensen-Jarolim E
Allergy; 2014 Feb; 69(2):137-49. PubMed ID: 24117861
[TBL] [Abstract][Full Text] [Related]
14. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells.
Luiten RM; Warnaar SO; Schuurman J; Pasmans SG; Latour S; Daëron M; Fleuren GJ; Litvinov SV
Hum Antibodies; 1997; 8(4):169-80. PubMed ID: 9395919
[TBL] [Abstract][Full Text] [Related]
15. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
Spicer J; Basu B; Montes A; Banerji U; Kristeleit R; Miller R; Veal GJ; Corrigan CJ; Till SJ; Figini M; Canevari S; Barton C; Jones P; Mellor S; Carroll S; Selkirk C; Nintos G; Kwatra V; Funingana IG; Doherty G; Gould HJ; Pellizzari G; Nakamura M; Ilieva KM; Khiabany A; Stavraka C; Chauhan J; Gillett C; Pinder S; Bax HJ; Josephs DH; Karagiannis SN
Nat Commun; 2023 Jul; 14(1):4180. PubMed ID: 37491373
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
17. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.
Gould HJ; Mackay GA; Karagiannis SN; O'Toole CM; Marsh PJ; Daniel BE; Coney LR; Zurawski VR; Joseph M; Capron M; Gilbert M; Murphy GF; Korngold R
Eur J Immunol; 1999 Nov; 29(11):3527-37. PubMed ID: 10556807
[TBL] [Abstract][Full Text] [Related]
18. IgE immunotherapy against cancer.
Leoh LS; Daniels-Wells TR; Penichet ML
Curr Top Microbiol Immunol; 2015; 388():109-49. PubMed ID: 25553797
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer.
Karagiannis SN; Josephs DH; Bax HJ; Spicer JF
Cancer Res; 2017 Jun; 77(11):2779-2783. PubMed ID: 28526770
[TBL] [Abstract][Full Text] [Related]
20. Animal models for IgE-meditated cancer immunotherapy.
Daniels TR; Martínez-Maza O; Penichet ML
Cancer Immunol Immunother; 2012 Sep; 61(9):1535-46. PubMed ID: 22193986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
